Unknown

Dataset Information

0

Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD.


ABSTRACT: Graft-versus-host disease (GvHD) is still the major non-relapse, life-limiting complication after hematopoietic stem cell transplantation. Modern pharmacologic immunosuppression is often insufficient and associated with significant side effects. Novel treatment strategies now include adoptive transfer of ex vivo expanded regulatory T cells (Tregs), but their efficacy in chronic GvHD is unknown. We treated three children suffering from severe, therapy-refractory GvHD with polyclonally expanded Tregs generated from the original stem cell donor. Third-line maintenance immunosuppression was tapered to cyclosporin A and low-dose steroids shortly before cell transfer. Regular follow-up included an assessment of the subjective and objective clinical development, safety parameters, and in-depth immune monitoring. All patients showed marked clinical improvement with substantially decreased GvHD activity. Laboratory follow-up showed a significant enhancement of the immunologic engraftment, including lymphocytes and dendritic cells. Monitoring the fate of Tregs by next-generation sequencing demonstrated clonal expansion. In summary, adoptive transfer of Tregs was well tolerated and able to modulate an established undesired T cell mediated allo-response. Although no signs of overimmunosuppression were detectable, the treatment of patients with invasive opportunistic infections should be undertaken with caution. Further controlled studies are necessary to confirm these encouraging effects and eventually pave the way for adoptive Treg therapy in chronic GvHD.

SUBMITTER: Landwehr-Kenzel S 

PROVIDER: S-EPMC9171381 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD.

Landwehr-Kenzel Sybille S   Müller-Jensen Leonie L   Kuehl Joern-Sven JS   Abou-El-Enein Mohamed M   Hoffmann Henrike H   Muench Sandra S   Kaiser Daniel D   Roemhild Andy A   von Bernuth Horst H   Voeller Mirjam M   Schmueck-Henneresse Michael M   Gruhn Bernd B   Stervbo Ulrik U   Babel Nina N   Volk Hans-Dieter HD   Reinke Petra P  

Molecular therapy : the journal of the American Society of Gene Therapy 20220228 6


Graft-versus-host disease (GvHD) is still the major non-relapse, life-limiting complication after hematopoietic stem cell transplantation. Modern pharmacologic immunosuppression is often insufficient and associated with significant side effects. Novel treatment strategies now include adoptive transfer of ex vivo expanded regulatory T cells (Tregs), but their efficacy in chronic GvHD is unknown. We treated three children suffering from severe, therapy-refractory GvHD with polyclonally expanded Tr  ...[more]

Similar Datasets

| S-EPMC7189290 | biostudies-literature
| S-EPMC2696596 | biostudies-literature
| S-EPMC5016253 | biostudies-literature
2023-04-14 | GSE229607 | GEO
| S-EPMC8250091 | biostudies-literature
2010-04-07 | E-GEOD-21073 | biostudies-arrayexpress
2010-03-26 | GSE21073 | GEO
| S-EPMC4990850 | biostudies-other
| S-EPMC2704307 | biostudies-literature